2024/02/02 更新

写真a

ノセ　タカユキ
能勢　隆之
Takayuki Nose
所属
多摩永山病院 放射線治療科 臨床教授
職名
臨床教授
プロフィール
1991 大阪大学医学部卒業
2009-日本医科大学多摩永山病院
外部リンク

論文

  • A Japanese prospective multi-institutional feasibility study on accelerated partial breast irradiation using multicatheter interstitial brachytherapy: clinical results with a median follow-up of 60 months 査読

    Ken Yoshida, Takayuki Nose, Yuki Otani, Shuuji Asahi, Iwao Tsukiyama, Takushi Dokiya, Toshiaki Saeki, Ichirou Fukuda, Hiroshi Sekine, Yu Kumazaki, Takao Takahashi, Tadayuki Kotsuma, Norikazu Masuda, Eisaku Yoden, Kazutaka Nakashima, Taisei Matsumura, Shino Nakagawa, Seiji Tachiiri, Yoshio Moriguchi, Jun Itami, Masahiko Oguchi

    Breast Cancer   29 ( 4 )   636 - 644   2022年7月

    　詳細を見る

    掲載種別：研究論文（学術雑誌）  

    Background: We carried out the first multi-institutional prospective study on accelerated partial breast irradiation (APBI) via multicatheter interstitial brachytherapy in a shorter period for early breast cancer in Japan. Methods: Patient eligibility criteria included positive hormone receptors, tumors ≤ 3 cm and TNM stage pN0M0. After breast-conserving surgery (Japanese cylindrical resection) and histological confirmation of negative surgical margins and the absence of lymph node metastasis, applicator implantation was performed either postoperatively or intraoperatively. High-dose-rate brachytherapy of 36 Gy in 6 fractions was delivered. Results: Forty-six patients from six institutions received this treatment regimen, and the median follow-up time was 60 months (range 57–67 months). The median resected breast tissue volume was 81 cm3 (range 28–260 cm3). No Grade 4 late sequela, local recurrence nor death due to breast cancer were observed. Grade 2–3 sequelae such as rib fracture (2%), soft tissue necrosis (9%), fibrosis (20%), and breast pain (9%) were observed. The resected breast tissue volumes of the patients who had Grade ≥ 2 fibrosis and Grade < 2 fibrosis were 105.9 ± 32.3 cm3 and 76.3 ± 45.6 cm3, respectively, p = 0.02. The overall cosmetic outcome score of Excellent/Good was 74% at 60 months after APBI. Grade ≥ 1 fibrosis was observed in 44% and 92% of patients who scored Excellent/Good and Fair/Poor, respectively, p = 0.004. Conclusions: This study showed excellent local control and survival results with minimal late sequelae.

    DOI： 10.1007/s12282-022-01339-z

    Scopus

    PubMed

    researchmap

  • An easy and novel method for safer brachytherapy: Real-time fluoroscopic verification of high-dose-rate 192 Ir source position using a flat-panel detector 査読 国際誌

    Takayuki Nose, Koji Masui, Tadashi Takenaka, Hideya Yamazaki, Katsuya Nakata, Yuki Otani, Shinichiro Kumita

    Journal of Radiation Research   60   412 - 415   2019年5月

    　詳細を見る

    担当区分：筆頭著者  

    © The Author(s) 2019. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Radiation Oncology. Real-time fluoroscopic verification of the active source position during actual treatment is the only established method to prevent high-dose-rate (HDR) brachytherapy events. The challenge is spurious signals from an HDR 192 Ir source that result in image halation, making source positions indiscernible when using a non-modified image intensifier fluoroscope. We have previously reported a method for observing an HDR 192 Ir source by using an elaborately modified image intensifier system. The newly developed flat-panel detector fluoroscope is, by contrast, inherently halation-free thanks to the wider dynamic range (12-14 bits), compared with image intensifier fluoroscopes (8 bits). To explore the feasibility, we applied a commercially available flat-panel detector fluoroscope without modification to actual treatment. We successfully observed source positions without halation for all 107 patients, with a total of 522 HDR treatment sessions during a 3-year period from 2014 to 2017. Actual source positions were compared with planned positions on the planning hard copy. With this method, we detected a total of 1 error (0.2%) among the 522 sessions, at a similar detection rate of 0.1% with our previous experience using a modified image intensifier fluoroscope. We found that a commercially available flat-panel detector fluoroscope is ready for use for real-time verification and outweighs the need for elaborate modifications of an image intensifier fluoroscope. A flat-panel detector fluoroscope will help the global radiation oncology community promote real-time verification programs, leading to safer HDR brachytherapy.

    DOI： 10.1093/jrr/rrz013

    Scopus

    PubMed

    researchmap

  • Real-Time Verification of a High-Dose-Rate Iridium 192 Source Position Using a Modified C-Arm Fluoroscope 査読

    Takayuki Nose, Masashi Chatani, Yuki Otani, Teruki Teshima, Shinichirou Kumita

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   97 ( 4 )   858 - 865   2017年3月

    　詳細を見る

    担当区分：筆頭著者   記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：ELSEVIER SCIENCE INC  

    Purpose: High-dose-rate (HDR) brachytherapy misdeliveries can occur at any institution, and they can cause disastrous results. Even a patient's death has been reported. Misdeliveries could be avoided with real-time verification methods. In 1996, we developed a modified C-arm fluoroscopic verification of an HDR Iridium 192 source position prevent these misdeliveries. This method provided excellent image quality sufficient to detect errors, and it has been in clinical use at our institutions for 20 years. The purpose of the current study is to introduce the mechanisms and validity of our straightforward C-arm fluoroscopic verification method.
    Methods and Materials: Conventional X-ray fluoroscopic images are degraded by spurious signals and quantum noise from Iridium 192 photons, which make source verification impractical. To improve image quality, we quadrupled the C-arm fluoroscopic X-ray dose per pulse. The pulse rate was reduced by a factor of 4 to keep the average exposure compliant with Japanese medical regulations. The images were then displayed with quarter-frame rates.
    Results: Sufficient quality was obtained to enable observation of the source position relative to both the applicators and the anatomy. With this method, 2 errors were detected among 2031 treatment sessions for 370 patients within a 6-year period.
    Conclusions: With the use of a modified C-arm fluoroscopic verification method, treatment errors that were otherwise overlooked were detected in real time. This method should be given consideration for widespread use. (C) 2016 Elsevier Inc. All rights reserved.

    DOI： 10.1016/j.ijrobp.2016.12.005

    Web of Science

    PubMed

    researchmap

  • HDR-brachytherapy for accelerated partial breast irradiation: Long-term experience from a Japanese institution. 査読 国際誌

    Ken Yoshida, Tadayuki Kotsuma, Yuji Takaoka, Setsuo Tamenaga, Hideya Yamazaki, Takayuki Nose, Naoya Murakami, Koji Inaba, Hironori Akiyama, Koji Masui, Tadashi Takenaka, Hikaru Kubota, Nikolaos Tselis, Norikazu Masuda, Hiroyuki Yasojima, Masashi Takeda, Masayuki Mano, Satoaki Nakamura, Keita Utsunomiya, Noboru Tanigawa, Eiichi Tanaka

    Journal of contemporary brachytherapy   15 ( 1 )   1 - 8   2023年2月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    PURPOSE: We investigated the long-term oncological outcome of high-dose-rate (HDR) multicatheter interstitial brachytherapy (MIB) for adjuvant accelerated partial breast irradiation (APBI) after breast conserving surgery in Japanese patients. MATERIAL AND METHODS: Between June 2002 and October 2011, 86 breast cancer patients were treated at National Hospital Organization Osaka National Hospital (trial number of the local institutional review board, 0329). Median age was 48 years (range, 26-73 years). Eighty patients had invasive and 6 patients non-invasive ductal carcinoma. Tumor stage distribution was pT0 in 2, pTis in 6, pT1 in 55, pT2 in 22, and pT3 in one patient, respectively. Twenty-seven patients had close/positive resection margins. Total physical HDR dose was 36-42 Gy in 6-7 fractions. RESULTS: At a median follow-up of 119 months (range, 13-189 months), the 10-year local control (LC) and overall survival rate was 93% and 88%, respectively. Concerning the 2009 Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology risk stratification scheme, the 10-year LC rate was 100%, 100%, and 91% for patients considered as low-risk, intermediate-risk, and high-risk, respectively. According to the 2018 American Brachytherapy Society risk stratification scheme, the 10-year LC rate was 100% and 90% for patients 'acceptable' and 'unacceptable' for APBI, respectively. Wound complications were observed in 7 patients (8%). Risk factors for wound complications were the omission of prophylactic antibiotics during MIB, open cavity implantation, and V100 ≥ 190 cc. No grade ≥ 3 late complications (CTCVE version 4.0) were observed. CONCLUSIONS: Adjuvant APBI using MIB is associated with favorable long-term oncological outcomes in Japanese patients for low-risk, intermediate-risk, and acceptable groups of patients.

    DOI： 10.5114/jcb.2023.125579

    PubMed

    researchmap

  • わが国でAPBIを普及させるには 招待 査読

    能勢隆之

    乳癌の臨床   35 ( 1 )   45 - 52   2020年

    　詳細を見る

    担当区分：筆頭著者  

    researchmap

  • 組織内照射を使った乳房加速部分照射APBIの現状 招待 査読

    能勢隆之, 大谷侑輝, 小ロ正彦

    乳癌の臨床   30 ( 3 )   199 - 205   2015年

    　詳細を見る

    担当区分：筆頭著者  

    researchmap

  • 3cm以下pN0M0女性乳癌に対する組織内照射を使った乳房加速部分照射法の第I相臨床試験プロトコールについて 査読

    能勢隆之, 内野三菜子, 土器屋卓志, 余田栄作, 平塚純一, 吉田謙

    日本放射線腫瘍学会誌   20 ( 2 )   78 - 79   2008年

    　詳細を見る

    担当区分：筆頭著者  

    researchmap

  • 【限局性前立腺癌の治療の現状と展望】放射線治療(外部照射)

    五味 光太郎, 小塚 拓洋, 熊田 まどか, 田原 誉敏, 大城 佳子, 根本 景子, 能勢 隆之, 小口 正彦, 山下 孝

    癌の臨床   53 ( 4 )   223 - 229   2007年8月

    　詳細を見る

  • 乳癌APBI-日本人への適用、外科医がAPBIに期待すること APBIの日本人への適応 招待

    能勢隆之

    臨床放射線   52   269 - 272   2007年

    　詳細を見る

    担当区分：筆頭著者  

    researchmap

  • 乳癌APBI-日本人への適用、外科医がAPBIに期待すること はじめに 招待

    能勢隆之

    臨床放射線   52   265 - 267   2007年

    　詳細を見る

    担当区分：筆頭著者  

    researchmap

  • ガラス線量計Dose Aceを使った組織内照射における線量実測 骨盤部腫瘍66例における1,084点の実測

    能勢 隆之, 小泉 雅彦, 吉田 謙, 佐々木 潤一, 大西 毅, 西山 謹司, 熊田 まどか, 田原 誉敏, 大城 佳子, 小塚 拓洋, 五味 光太郎, 小口 正彦, 高橋 豊, 山下 孝

    日本放射線腫瘍学会誌   17 ( 4 )   233 - 233   2006年1月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本放射線腫瘍学会  

    researchmap

  • ガラス線量計Dose Aceを用いた組織内照射における線量実測 骨盤部1,004点の実測

    能勢 隆之, 小泉 雅彦, 吉田 謙, 佐々木 潤一, 西山 謹司, 小塚 拓洋, 五味 光太郎, 小口 正彦, 高橋 豊, 山下 孝

    日本放射線腫瘍学会誌   17 ( Suppl.1 )   101 - 101   2005年10月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本放射線腫瘍学会  

    researchmap

  • 外来重点治療（入院から外来へ）（４）小線源放射線治療 査読

    能勢隆之, 菰池佳史, 吉田謙, 元村和由, 稲治英生, 小泉雅彦, 西山謹司, 小山博紀

    乳癌の臨床   20 ( 2 )   125 - 130   2005年2月

    　詳細を見る

    担当区分：筆頭著者  

    researchmap

  • The usefulness of metal markers for CTV-based dose prescription in high-dose-rate interstitial brachytherapy

    Ken Yoshida, Takayuki Nose, Masahiko Koizumi, Masanori Mitomo, Kinji Nishiyama, Mineo Yoshida

    Journal of JASTRO   14 ( 4 )   253 - 260   2002年12月

    　詳細を見る

    掲載種別：研究論文（学術雑誌）  

    Purpose: We employ a clinical target volume (CTV)-based dose prescription for high-dose-rate (HDR) interstitial brachytherapy. However, it is not easy to define CTV and organs at risk (OAR) from X-ray film or CT scanning. To solve this problem, we have utilized metal markers since October 1999. Moreover, metal markers can help modify dose prescription. By regulating the doses to the metal markers, refining the dose prescription can easily be achieved. In this research, we investigated the usefulness of the metal markers. Methods and Materials: Between October 1999 and May 2001, 51 patients were implanted with metal markers at Osaka Medical Center for Cancer and Cardiovascular Diseases (OMCC), Osaka National Hospital (ONH) and Sanda City Hospital (SCH). Forty-nine patients (head and neck: 32; pelvis: 11: soft tissue: 3; breast: 3) using metal markers were analyzed. During operation, we implanted 179 metal markers (49 patients) to CTV and 151 markers (26 patients) to OAR. At treatment planning, CTV was reconstructed judging from the metal markers, applicator position and operation records. Generally, we prescribed the tumoricidal dose to an isodose surface that covers CTV. We also planned to limit the doses to OAR lower than certain levels. The maximum normal tissue doses were decided 80%, 150%, 100%, 50% and 200% of the prescribed doses for the rectum, the urethra, the mandible, the skin and the large vessel, respectively. The doses to the metal markers using CTV-based dose prescription were generated. These were compared with the doses theoretically calculated with the Paris system. Treatment results were also investigated. Results: The doses to the 158 metal markers (42 patients) for CTV were higher than "tumoricidal dose". In 7 patients, as a result of compromised dose prescription, 9 markers were lower than the tumoricidal dose. The other 12 markers (7%) were excluded from dose evaluation because they were judged as miss-implanted. The doses to the 142 metal markers (24 patients) for OAR were lower than the maximum normal tissue doses. The doses of 2 markers (1 patient) for OAR (the urethra) were higher than the maximum normal tissue dose. Seven markers for OAR (the mandible) were not visualized because of metal crowns. If the Paris system (reference dose is prescribed to an isodose surface of 85% of the basal dose) had been used, 16 patients had been "underdosed" and 4 patients (the rectum + the urethra: 2; the urethra: 1 the large vessel: 1) "overdosed". Dose non-uniformity ratio (DNR) and maximum diameter of hyperdose sleeve were 0.31 ± 0.08 and 4-49 mm (median: 7 mm) in CTV-based dose prescription. A statistically significant difference was seen between CTV-based dose prescription and Paris system {0.28 ± 0.08 and 3-99 mm (median: 6 mm)} (p<0.002, 0.0002). Two of 42 patients treated with higher than the tumoricidal dose had local recurrence, while 4 of 7 underclosed patients had local recurrence. A significant difference was found between them (p<0.0001). Conclusions: Metal markers were useful to prescribe the tumoricidal dose to CTV and to regulate the doses for OAR. Local control rate of the patients treated with higher than the tumoricidal dose was significantly better. Miss-implantation of metal markers was a problem that should be resolved.

    Scopus

    researchmap

  • CTV-based Dose Prescriptionにおける金属マーカーの有効性

    吉田 謙, 能勢 隆之, 小泉 雅彦, 吉田 岑雄, 西山 謹司, 御供 政紀

    日本医学放射線学会雑誌   62 ( 3 )   S177 - S177   2002年3月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本医学放射線学会  

    researchmap

  • Lumpectomy+組織内照射単独による乳房温存療法

    能勢 隆之, 小泉 雅彦, 西山 謹司, 吉田 謙

    日本医学放射線学会雑誌   62 ( 3 )   S256 - S256   2002年3月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本医学放射線学会  

    researchmap

  • わが国での医療実態調査研究による前立腺癌根治的外照射の現状-コンフォーマル照射の有無による治療成績の検討- 査読

    中村和正, 手島昭樹, 高橋豊, 今井敦, 小泉雅彦, 能勢隆之, 三橋紀夫, 井上俊彦

    日本ＰＣＳ前立腺癌小線源部会. 泌尿器外科   15 ( 8 )   849 - 852   2002年

    　詳細を見る

    記述言語：日本語   出版者・発行元：医学図書出版(株)  

    医療実態調査研究により得られた,前立腺癌の根治的放射線治療の現状について報告し,特に,コンフォーマル照射の有無による治療成績等について検討した.内分泌療法併用例を含む根治的外照射例162例の解析ではhigh risk例が多く,86.3%に内分泌療法が併用されており,前立腺局所に対する照射線量は中央値65Gyとやや少なかった.コンフォーマル照射は49.4%で行われていた.経過観察期間中央値27.5ヵ月において,3年の時点でのoverall survival rateは86.7%,biochemical relapse free survival rateは86.1%と良好であり,コンフォーマル照射の有無によるsurvival rateに差はなかった.晩期有害事象は9例に認められ,コンフォーマル照射例にやや少ない傾向にあったが,照射線量が少ないためか,通常照射に対する有用性は明らかではなかった

    researchmap

  • 中咽頭癌に対する高線量率組織内照射． 招待

    能勢隆之, 小泉雅彦, 西山謹司, 吉田謙, 井上俊彦

    頭頸部腫瘍   28 ( 1 )   198 - 204   2002年

    　詳細を見る

  • 高線量率組織内照射と低線量率組織内照射の後期正常粘膜組織（中咽頭口腔粘膜）変化の比較． 査読

    能勢隆之, 小泉雅彦, 西山謹司, 井上俊彦

    日本放射線腫瘍学会誌   14 ( 19 )   15 - 20   2002年

    　詳細を見る

    担当区分：筆頭著者   記述言語：日本語  

    CiNii Books

    CiNii Research

    researchmap

  • 組織内照射における金属マーカーの有用性 ＣＴＶ‐ｂａｓｅｄ Ｄｏｓｅ Ｐｒｅｓｃｒｉｐｔｉｏｎへの応用—CTV-based Dose Prescriptionへの応用

    吉田 謙, 能勢 隆之, 小泉 雅彦, 御供 政紀, 西山 謹司, 吉田 岑雄

    日本放射線腫瘍学会誌   14 ( 4 )   253 - 260   2002年

    　詳細を見る

    記述言語：日本語   出版者・発行元：一般社団法人 日本放射線腫瘍学会  

    【背景および目的】我々は高線量率組織内照射においてclinicaltarget volume (CTV)-based Dose prescriptionを施行している. 治療計画時にはCTVとOrgans at risk (OAR) を再構成するため, 金属マーカーを利用している. 金属マーカーの有効性を検証した.<BR>【方法と対象】1999年10月から2001年5月までに大阪府立成人病センター, 国立大阪病院および三田市民病院でImplantを施行した51例中, 金属マーカーを用いた49例 (頭頸部32, 骨盤部11, 骨軟部3, 乳腺3) を対象とした. アプリケータ刺入時に,(1) CTVの辺縁に49例179個,(2) OARに26例151個の金属マーカーを刺入・留置した. 刺入時に記録したCTVとマーカー, アプリケータとの位置関係から治療計画にCTVを再構成した. CTVを囲むIsodosesur faceへ抗腫瘍線量を投与するように計画した, OARへの投与線量は直腸, 尿道, 下顎骨, 皮膚, 大血管についてそれぞれ抗腫瘍線量の80%, 150%, 100%, 50%, 200%以下を目標とした. 金属マーカーの線量, パリ法で計画した場合との比較 (マーカーの線量, DNR, Hyperdose sleeve), 初期治療成績を検討課題とした.<BR>【結果】(1) CTV用の金属マーカー179個中158個 (42例) は抗腫瘍線量以上となった. 9個 (7症例) はOARへの影響を考え投与線量を下げた. 残りの12個 (7%) は金属マーカー刺入が不適切であったため計画対象外とした.(2) OARについては尿道内の2綱 (1例) のみが目標線量以上となった.(3) 下顎骨のマーカーは7個が金属歯冠のため同定できなかった.(4) パリ法で計画した場合, 16例のCTV用金属マーカーが抗腫瘍線量以下となった. OARについては, 4例 (直腸+尿道2, 尿道1, 大血管1) が目標線量以上となった.(5) CTV-based Dose prescriptionでは, DNRが0.31±0.08, Hyperdose sleeveが4～49mm (中央値7mm) となり, パリ法 {DNR: 0.28士0.08;Hyperdose sleeve: 3～99mm (中央値6mm)} と比較して有意差を認めた (p<0.002, 0.0002).(6) 局所制御率は88%(43例) であった, 抗腫瘍線量以上を投与できた42例中2例のみが再発したのに対し, 投与できなかった7例中4例が再発した (p<0.0001).<BR>【結論と考察】金属マーカーにより, CTVに対する抗腫瘍線量の投与を正確に行うことができた. OARへの線盤を調節できた. 再抗腫瘍線量を投与できなかった症例は有意に局所制御率が不良であった.

    DOI： 10.11182/jastro1989.14.253

    CiNii Books

    CiNii Research

    researchmap

  • 中咽頭癌に対する高線量率組織内照射

    能勢 隆之, 小泉 雅彦, 西山 謹司, 吉田 謙, 井上 俊彦

    日本放射線腫瘍学会誌   13 ( Suppl.1 )   82 - 82   2001年10月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本放射線腫瘍学会  

    researchmap

  • Dosimetry of interstitial brachytherapy using radiophotoluminescence glass: On absorbed dose of anterior wall of the rectum

    T. Nose, M. Koizumi, K. Nishiyama, K. Yoshida

    Nihon Igaku Hōshasen Gakkai zasshi. Nippon acta radiologica   61 ( 10 )   540 - 542   2001年9月

    　詳細を見る

    掲載種別：研究論文（学術雑誌）  

    It has been almost impossible to perform in-vivo dosimetry of interstitial brachytherapy because of the lack of appropriate dosimeters. The newly developed photoluminescence dosimeter "Dose Ace" is suitable for interstitial brachytherapy dosimetry in terms of its small size, ease of handling, and good reproducibility. We performed dosimetry of the anterior rectal wall by suturing a Teflon tube containing photoluminescence dosimeters. We measured doses at 50 points in seven pelvic malignancy patients and calculated the dose at each point by planning computer. The mean ratio of measured dose to calculated dose was 1.108 to 0.213. The absorbed dose of the anterior rectal wall can be presumed from the calculated dose with about 10% deviation.

    Scopus

    PubMed

    researchmap

  • 前立腺癌に対する高線量率組織内照射

    能勢 隆之, 小泉 雅彦, 西山 謹司, 吉岡 靖生, 井上 俊彦, 吉田 謙

    Radiology Frontier   4 ( 3 )   246 - 248   2001年8月

    　詳細を見る

  • PCSによる放射線治療の現状 PCSによる前立腺癌に対する放射線治療の現状

    中村和正, 手島昭樹, 高橋豊, 今井敦, 小泉雅彦, 能勢隆之, 三橋紀夫, 井上俊彦

    癌の臨床   47 ( 8 )   693 - 699   2001年8月

    　詳細を見る

    記述言語：日本語  

    J-GLOBAL

    researchmap

  • PCSによる放射線治療の現状 PCSによるわが国における小線源治療の現状

    小泉雅彦, 中村和正, 今井敦, 能勢隆之, 井上俊彦, 手島昭樹, 高橋豊

    癌の臨床   47 ( 8 )   701 - 709   2001年8月

    　詳細を見る

    記述言語：日本語  

    J-GLOBAL

    researchmap

  • 中咽頭癌に対する高線量率組織内照射

    能勢 隆之, 小泉 雅彦, 西山 謹司, 吉田 謙, 井上 俊彦

    頭頸部腫瘍   27 ( 2 )   512 - 512   2001年5月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本頭頸部癌学会  

    researchmap

  • ガラス線量計を用いた組織内照射の実測-直腸前壁の線量について 査読

    能勢隆之, 小泉雅彦, 西山謹司, 吉田謙

    日本医学放射線学会雑誌   61 ( 10 )   540 - 542   2001年

    　詳細を見る

    担当区分：筆頭著者   記述言語：日本語   出版者・発行元：(公社)日本医学放射線学会  

    骨盤部へ高線量率組織内照射を施行した7名を対象とし,テフロンチューブ内直列法及び直腸前壁縫着法を使って線量実測を行った.内訳は,前立腺癌2名,子宮頸癌5名であった.直腸前壁における実測線量と計算線量において,グラフは大まかには一致した.全50ヶ所における実測線量/計算線量の比は,平均1.108±0.213で範囲は0.78〜1.768であった.よって,直腸前壁の線量は,計算値から推測可能であった.但し,10%強の誤差を含むことに留意すべきである

    researchmap

    その他リンク： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2001&ichushi_jid=J01021&link_issn=&doc_id=20011018020003&doc_link_id=1050845762616903936&url=https%3A%2F%2Fcir.nii.ac.jp%2Fcrid%2F1050845762616903936&type=CiNii&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00003_3.gif

  • 日本とフランスの頭頸部癌組織内照射の比較 査読

    能勢隆之, 小泉雅彦, 西山謹司, 井上俊彦

    頭頸部腫瘍   27 ( 1 )   158 - 165   2001年

    　詳細を見る

  • 日本とフランスの頭頸部癌組織内照射の比較

    能勢 隆之, 西山 謹司, 小泉 雅彦, 井上 俊彦

    頭頸部腫瘍   26 ( 2 )   349 - 349   2000年5月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本頭頸部癌学会  

    researchmap

  • Ｍｉｃｒｏ‐Ｍｕｌｔｉ‐Ｌｅａｆ（ｍ３）を用いた頭頚部癌の定位放射線治療

    西山 謹司, 小泉 雅彦, 能勢 隆之, 吉野 邦俊

    頭頸部腫瘍   26 ( 1 )   127 - 132   2000年

    　詳細を見る

    記述言語：日本語   出版者・発行元：日本頭頸部癌学会  

    放射線治療の適応とされることが多い頭頸部癌の複雑な解剖学的環境は大きな課題を提供しているが, 定位照射では腫瘤に対する高精度の照射野の設定が可能で危険臓器の回避も容易である。Micro-Multi-Leaf (m3TM) を用いて13例の頭頸部腫瘍に定位照射を行った。対象では外部照射後の追加定位照射が6例と最も多く, 術後予防照射が3例であった。患者固定はシェルで, 2.5mm厚で病変部のCTを行い, CT画像に標的, 危険臓器 (眼球, 脊髄, 耳下腺) を設定したうえで, 照射野を作成した。標的容積は3.6-105.6mlで, 4-7門の non-coplanar 固定照射野で照射した。投与線量は1回2.5-4Gy, 総量15-62.5Gyであり, 標的, 危険臓器の線量を評価, 検討した。中心線量に対する標的内の最大線量は102-112%であり, 線量分布の平坦性は良好で, 危険臓器に対する線量は低減された。

    DOI： 10.5981/jjhnc1974.26.127

    CiNii Research

    researchmap

  • Micro-Multi-Leaf(M3)を用いた頭頸部癌の定位放射線治療

    西山 謹司, 小泉 雅彦, 茶谷 正史, 能勢 隆之, 真崎 規江, 寺田 友紀, 桃原 実大, 長原 昌萬, 藤井 隆, 稲上 憲一

    頭頸部腫瘍   25 ( 2 )   254 - 254   1999年5月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本頭頸部癌学会  

    researchmap

  • 子宮頸癌術後照射例の検討 予後因子と合併症

    茶谷 正史, 小泉 雅彦, 能勢 隆之, 西山 謹司, 井上 俊彦

    日本医学放射線学会雑誌   59 ( 2 )   S223 - S223   1999年2月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本医学放射線学会  

    researchmap

  • Renal cortical retention on delayed CT after angiography and contrast associated nephropathy

    H Yamazaki, H Oi, M Matsushita, T Inoue, T Teshima, M Koizumi, T Nose, E Tanaka, H Nakamura, T Inoue, T Kim, MM Elbaradie

    BRITISH JOURNAL OF RADIOLOGY   70 ( 837 )   897 - 902   1997年9月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：BRITISH INST RADIOLOGY  

    The aim of this study was to examine the relationship between renal cortical retention (RCR) of contrast media observed on delayed CT (median delay: 20 h) and contrast associated nephropathy (CAN). We investigated the incidence of both phenomena in 270 patients. CAN was defined as an increase in the creatinine level &gt; 0.5 mg dl(-1) (44 mu mol l(-1)) and &gt; 25% on day 1, 3 or 7, while RCR was recognized when CT values for the renal cortex showed either mild RCR (CT value &gt; 50) or severe RCR (CT value &gt; 100). RCR was demonstrated in 127 patients (47%), mild in 78 (29%) and severe in 49 (18%), on delayed CT after angiography. CAN was found in eight patients (3%). Patients with severe RCR showed a higher CAN rate (8%) than other patients (mild RCR: 4%, RCR (-): 1%) (p=0.02). The type of contrast medium was independently associated with the incidence of RCR (p=0.0001). Although severe RCR was associated with a higher frequency of CAN than the milder forms of RCR, RCR as such was not always associated with CAN.

    Web of Science

    Scopus

    PubMed

    researchmap

  • Comparison of the long term results of brachytherapy for T1-2N0 oral tongue cancer treated with Ir-192 and Ra-226

    H Yamazaki, T Inoue, M Koizumi, K Yoshida, K Kagawa, H Shiomi, T Nose, E Tanaka, T Teshima, H Nakamura, K Shimizutani, S Furukawa, H Fuchihata, T Inoue

    ANTICANCER RESEARCH   17 ( 4A )   2819 - 2822   1997年7月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：INT INST ANTICANCER RESEARCH  

    Background: The authors report the compatibility of iridium-192 (Ir-192) to Radium-226 (Ra-226) based on the clinical results of three-decades. Methods: From 1967 through 1985, 119 patients with early oral tongue cancer (T1-2NO) were treated with conventional Ra-226 needles and 135 patients with Ir-192 hair pins. Results: Local cona ol rates at 10 years for T1 and T2 tongue cancer were 79% and 61% for patients treated with Ra-226, 83% and 68% with Ir-192. The 10-year cause-specific survival rates for the T1 and T2 patients with Ra-226 were 76% and 63%, and those with Ir-192 were 77% and 68%, respectively. Conclusions: Ir-192 showed good possibilities its a substitute for Ra-226 in brachytherapy for early oral tongue cancer.

    Web of Science

    researchmap

  • Lack of effect of hepatocyte growth factor on bone marrow suppression induced by total body irradiation in the rat

    Hideya Yamazaki, Takehiro Inoue, Jin Tian Tang, Takayuki Nose, Masahiko Koizumi, Eiichi Tanaka, Teruki Teshima, Shuji Ozeki, Hironobu Nakamura, Toshihiko Inoue

    Anticancer Research   17 ( 1 A )   479 - 480   1997年3月

    　詳細を見る

    掲載種別：研究論文（学術雑誌）  

    We examined the role of hepatocyte growth factor (HGF) on the bone marrow suppression by irradiation by analyzing peripheral blood counts 2 weeks after 7 Gy of total body irradiation in rats. The rats underwent two weeks of continuous intraperitoneal human recombinant HGF injection (50 mg/day) from one day before irradiation using an Alzet osmotic pump. Red blood cell, white blood cell and platelet counts did not increase with response to administration of HGF. Thus HGF does not show protection against myelosuppression caused by total body irradiation.

    Scopus

    PubMed

    researchmap

  • Lack of correlation between gallbladder opacification in delayed CT and contrast-associated nephropathy

    H Yamazaki, H Oi, M Matsushita, T Kim, M ElBaradie, T Inoue, T Teshima, M Koizumi, T Nose, E Tanaka, H Nakamura, T Inoue

    EUROPEAN RADIOLOGY   7 ( 8 )   1328 - 1331   1997年

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：SPRINGER VERLAG  

    The objective of our study was to determine the correlation between gallbladder opacification by delayed CT and contrast-associated nephropathy (CAN). Delayed CT after angiography was performed in 269 patients. Gallbladder opacification was defined when the CT value in gallbladder was more than 30 HU. Positive renal dysfunction was recognized as CAN which defined as an increase in serum creatine level &gt; 0.3 mg/dl and &gt; 20% on days 1, 3, or 7. Gallbladder opacification appeared in 154 of 269 (57%) patients and CAN in 35 (13%) patients. Of 117 patients without gallbladder opacification, 17 CAN (14%) were recognized, and of 152 patients with gallbladder opacification, 18 CAN (12%) were recognized. No significant correlation existed between delayed gallbladder opacification and CAN.

    DOI： 10.1007/s003300050297

    Web of Science

    Scopus

    PubMed

    researchmap

  • 舌・口腔底癌に対する高線量率分割組織内照射における治療容積の検討.

    井上 武宏, 井上 俊彦, 山崎 秀哉, 小泉 雅彦, 清水谷 公成, 村山 重行, 能勢 隆之, 手島 昭樹, 古川 惣平, 田中 英一, 渕端 孟

    頭頸部腫瘍   23 ( 1 )   19 - 23   1997年

    　詳細を見る

  • Renal cortical retention of contrast medium after angiography as assessed by delayed CT: A multivariate analysis

    H. Yamazaki, H. Oi, M. Matsushita, T. Inoue, S. Murayama, M. Koizumi, T. Nose, E. Tanaka, T. Teshima, K. Kagawa, T. Inoue

    Radiation Medicine - Medical Imaging and Radiation Oncology   14   247 - 250   1996年12月

    　詳細を見る

    Renal cortical retention (RCR) of contrast medium discovered by delayed X-ray examination is sometimes reported in patients with problems in the urinary system. However, we frequently found RCR even in patients with normal renal function. Therefore, we examined the incidence and factors involved in RCR by delayed computed tomography (CT) 12-24 hours after angiography in 168 patients. RCR was found in 80 of 168 cases (48%). Ioxaglate (60%) and iohexol (60%) showed higher incidences of RCR than diatrizoate (37%) and iopamidol (37%). Multivariate logistic regression analysis was performed to determine the predisposing factors of RCR. Dose of administered contrast medium by body weight (p = 0.004), age (p = 0.009), sex (p = 0.013), type of contrast medium (p = 0.003), serum albumin (p = 0.011), and serum creatinine (p = 0.002) were identified as significant and independent predisposing factors of RCR. We suggest that RCR is not a rare phenomenon if delayed CT is carried out.

    Scopus

    PubMed

    researchmap

  • 高線量率イリジウム治療 中咽頭癌 査読

    能勢隆之, 井上武宏, 井上俊彦, 田中英一, 手島昭樹, 塩見浩也, 吉田謙, 服部賢二, 吉田淳一

    臨床放射線   41 ( 13 )   1617 - 1621   1996年12月

    　詳細を見る

    担当区分：筆頭著者   記述言語：日本語  

    J-GLOBAL

    researchmap

  • 高線量率イリジウム治療 骨軟部

    吉田謙, 井上武宏, 小泉雅彦, 能勢隆之, 田中英一, 塩見浩也, 手島昭樹, 井上俊彦, 荒木信人

    臨床放射線   41 ( 13 )   1635 - 1638   1996年12月

    　詳細を見る

    記述言語：日本語   出版者・発行元：金原出版(株)  

    J-GLOBAL

    researchmap

  • 高線量率イリジウム治療 舌癌

    井上武宏, 能勢隆之, 井上俊彦, 手島昭樹, 田中英一, 香川一史, 小泉雅彦, 塩見浩也, 吉田謙

    臨床放射線   41 ( 13 )   1611 - 1615   1996年12月

    　詳細を見る

    記述言語：日本語   出版者・発行元：金原出版  

    CiNii Books

    J-GLOBAL

    researchmap

  • Gallbladder opacification 12-24 h after angiography by CT examination: A multivariate analysis

    H Yamazaki, H Oi, M Matsushita, T Inoue, T Teshima, S Murayama, T Nose, T Koizumi, E Tanaka, T Inoue

    ABDOMINAL IMAGING   21 ( 6 )   507 - 511   1996年11月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：SPRINGER VERLAG  

    Background: To examine the incidence and predisposing factors of gallbladder opacification in delayed computed tomography (CT) after angiography.
    Methods: CT examination 12-24 h after angiography was performed in 389 patients. Univariate and multivariate analyses were made.
    Results: Two hundred thirty-three of 389 patients (60%) revealed gallbladder opacification. Type of contrast medium (P &lt; 0.01), total bilirubin (P &lt; 0.01), and serum creatinine (P &lt; 0.01) were significant and independent factors relating to gallbladder opacification. Ioxaglate (70%, relative odds = 2.86) and iohexol (63%, relative odds = 2.03) showed higher gallbladder opacification rates than that of iopamidol (45%, relative odds = 1.43) and diatrizoate (30%). Patients with a lower serum bilirubin level (relative odds = 1.67) and a raised serum creatinine level (relative odds = 2.01) showed higher incidence of gallbladder opacification.
    Conclusion: Gallbladder opacification after angiography is not an abnormal finding on delayed CT in patients with not only abnormal renal function but also normal hepatobiliary and normal renal function, especially for modern contrast media.

    DOI： 10.1007/s002619900114

    Web of Science

    Scopus

    PubMed

    researchmap

  • Effect of hepatocyte growth factor on radiation response of HeLa, V79, CHO and primary cultured parenchymal hepatocyte in vitro 査読

    H. Yamazaki, T. Inoue, T. Nose, S. Murayama, T. Teshima, S. Ozeki, M. Koizumi, T. Inoue

    Radiation Medicine - Medical Imaging and Radiation Oncology   14 ( 2 )   81 - 85   1996年7月

    　詳細を見る

    掲載種別：研究論文（学術雑誌）  

    Hepatocyte growth factor (HGF) is a multipotent cytokine enhancing regeneration of injured organs as liver, kidney and lung after injury. HGF enhances proliferation of various type of cells, inhibits proliferation of carcinoma cells, enhances motility of epithelial cells. We examined three cell lines (CHO, HeLa, V79) and primary cultured normal rat parenchymal hepatocytes to determine the effect of HGF on radiation response. HGF diminished survival of CHO and V79 cells determined by colony formation assay, whereas no significant change of survival was found in HeLa cells. No synergistic changes of survival were found when these three cell lines were irradiated with the addition of HGF. Thus, HGF did not enhance the radiation effect. We also analyzed the impact of irradiation with HGF on primary cultured normal rat parenchymal hepatocytes. At first, the release of glutamic-oxaloacetic amino-transaminase (GOT) in the supernatant was estimated. Irradiation (40 Gy) with or without HGF did not change GOT release in acute phase by 4 days after irradiation compared with the unirradiated control. Second, the DNA synthesis of rat parenchymal hepatocytes was analyzed using radioactive iodine-labeled deoxyuridine incorporation. HGF counteracted the suppression of DNA synthesis induced by irradiation. Thus, HGF may act as a mitogen even for irradiation-damaged normal cells.

    Scopus

    PubMed

    researchmap

  • Effect of radiotherapy on serum level of interleukin 6 in patients with cervical carcinoma

    JT Tang, H Yamazaki, N Nishimoto, T Inoue, T Nose, M Koizumi, E Tanaka, A Ogata, K Yoshizaki, T Inoue

    ANTICANCER RESEARCH   16 ( 4A )   2005 - 2008   1996年7月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：INT INST ANTICANCER RESEARCH  

    To determine the inflammatory state of cervical cancer after radiotherapy, we examined serum interleukin 6 levels (sIL-6) and C-reactive protein (CRP) before and after radiation therapy in sixteen patients with cervical cancer. External radiation therapy did not cause changes in sIL-6 and CRP during the examined periods. On the other had, brachytherapy caused transient elevation of sIL-6 on the day after treatment by 6.39+/-1.89 pg/ml to 13.41+/-2.34 pg/ml (p&lt;0.05) while CRP did not show any significant change. Therefore, brachytherapy would induce a small inflammatory reaction. However, we confirmed that radiotherapy is a less invasive treatment than surgery from the point of view of cytokine related inflammation.

    Web of Science

    researchmap

  • Late local recurrence after radiotherapy for tongue and early glottic carcinoma

    Ta Inoue, To Inoue, T. Teshima, S. Murayama, T. Nose, E. Tanaka, H. Yamazaki, M. Koizumi, K. Kagawa, S. Ozeki, H. Ikeda

    Strahlentherapie und Onkologie   172   301 - 305   1996年6月

    　詳細を見る

    Background/Aim: Late local recurrence after radiotherapy for tongue and early glottic carcinoma is rarely discussed. In the head and neck cancer, approximately 90% of local recurrence occurred within 2 years after radiotherapy. However, we found that late local recurrence after radiotherapy for glottic cancer was not rare. Our aim was to evaluate the late local recurrence after radiotherapy for early glottic and tongue cancer. Patients and Methods: From 1967 through 1982, 633 patients with tongue carcinoma and 330 patients with early (T1T2N0) glottic carcinomas were treated at the Department of Radiology, Osaka University Hospital. Of these 821 patients, 329 patients with tongue carcinoma and 221 patients with early glottic carcinoma survived at 5 years after radiotherapy without local recurrence. For tongue carcinoma, patients were divided by T category. For early glottic carcinoma, patients were divided by the tumor response at 40 Gy. Results: Late local recurrence occurred in 23 of 329 patients (7%) with tongue carcinoma, and in 9 of 221 patients (4%) with early glottic carcinoma. For tongue carcinoma, late recurrence occurred in 19 of 249 patients (8%) in stage I and II, and 4 of 80 patients (5%) in stage III and IV. For glottic carcinoma, late recurrence occurred in 8 of 137 patients (6%) with tumor clearance at 40 Gy and 1 of 63 patients (2%) with tumor persistence at 40 Gy. The incidence of double cancer was also evaluated. Of 329 5-year survivors with tongue carcinoma, 39 patients (12%) had another malignancy, and 26 patients of 221 5-year survivors with early glottic carcinoma (2%) had also another malignancy. Of 39 double primaries of tongue carcinoma, 10 patients (26%) had head and neck malignancies, and none of 26 double primaries of early glottic carcinoma. Conclusion: Late local recurrence was not rare in tongue and early glottic cancer. Poor prognostic group showed lower incidence of late recurrence than good prognostic group. This result suggests that secondary tumor at the same site of primary tumor is late local recurrence.

    Scopus

    PubMed

    researchmap

  • 骨軟部腫ようにおける術中チューブ留置による高線量率分割組織内照射 査読

    小泉雅彦, 井上俊彦, 井上武宏, 手島昭樹, 大谷雅俊, 山崎秀哉, 能勢隆之, 福島祥子, 内田淳正

    日本医学放射線学会雑誌   56 ( 7 )   523 - 525   1996年6月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本医学放射線学会  

    J-GLOBAL

    researchmap

  • Focal residual contrast media in the kidney 24 hours after angiography 査読

    H Yamazaki, H Oi, M Matsushita, M Koizumi, K Kagawa, E Tanaka, S Murayama, T Nose, T Teshima, TA Inoue, TO Inoue

    ACTA RADIOLOGICA   37 ( 3 )   348 - 351   1996年5月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：MUNKSGAARD INT PUBL LTD  

    Purpose: To examine the relationship between focal renal cortical retention (FRCR) and contrast-associated nephropathy (CAN). Material and Methods: We investigated the incidence of both phenomena in 105 patients. CAN was defined as an increase in the creatinine level &gt;0.3 mg/dl and &gt;20% on days 1, 3, or 7. We compared predisposing factors for FRCR and CAN. Serum cre atinine and blood urea nitrogen (BUN) for renal function were determined on the morning of the day of the angiography. The BUN/creatinine ratio was used as an indicator of the degree of hydration. Results: FRCR was demonstrated in 17 patients (16%) by delayed CT 24 h after angiography, and CAN was found in 16 patients (15%). No significant relationship between CAN and FRCR was found. We found a correlation between high total volumes of contrast and FRCR. Advanced age, high blood urea nitrogen, high creatinine, and dehydration were risk factors for CAN.
    Conclusion: Delayed CT showed a higher incidence of injury to the renal parenchyma than previously detected by conventional radiography.

    DOI： 10.3109/02841859609177664

    Web of Science

    Scopus

    PubMed

    researchmap

  • Induction of hepatocyte growth factor in the liver, kidney and lung following total body irradiation in rat 査読

    Hideya Yamazaki, Kunio Matsumoto, Takehiro Inoue, Takayuki Nose, Shigeyuki Murayama, Teruki Teshima, Shuji Ozeki, Masahiko Koizumi, Toshikazu Nakamura, Toshihiko Inoue

    Cytokine   8   927 - 932   1996年1月

    　詳細を見る

    Hepatocyte growth factor (HGF) has been shown to have a pleiotropic function to act as a potent organotropic factor in the regeneration of injury in various organs, including the liver, kidney and lung. To examine the involvement of HGF in radiation injury, the authors analysed the changes in HGF mRNA and HGF protein levels in the rat organs (liver, lung, kidney) and plasma following 6 Gy of total body irradiation. Expression of HGF mRNA in the liver and kidney increased 6-48 h after total body irradiation and returned to previous values 1 week later. HGF protein levels in lung and liver showed 1.3-2-fold elevations 1-2 weeks after irradiation (P &lt; 0.05). HGF levels in plasma stayed at undetectable levels up to 1 month after total body irradiation. The labelling index determined 2 weeks and 1 month after total body irradiation indicated no enhancement of regeneration. Thus, total body irradiation induced transient HGF elevation in these organs without enhancement of regeneration.

    DOI： 10.1006/cyto.1996.0124

    Scopus

    PubMed

    researchmap

  • High dose rate brachytherapy using a template technique for pelvic malignancies 査読

    H. Yamazaki, T. Inoue, M. Koizumi, S. Murayama, T. Teshima, E. Tanaka, T. Nose, S. Fukushima, K. Ohashi, T. Inoue

    Endocurietherapy/Hyperthermia Oncology   12   145 - 152   1996年1月

    　詳細を見る

    Eleven patients with recurrent cancers in the pelvic area (nine gynecologic cancers and two rectal cancers) were treated at Osaka University Hospital with high dose rate (HDR) brachytherapy using a template technique. Twice-a-day irradiation with the Nucletron microSelectron HDR (24 to 50 Gy; four to ten fractions during two to six days) was performed. Of nine patients with gynecologic tumors, five achieved complete response, three achieved partial response, and one registered no change. Almost all patients showed tumor regression and/or good palliation. In gynecologic malignancies, we encountered four fistulae and a hydronephrosis that required an artificial stoma and/or urinary tract during the follow-up periods (ten to 33 months; median, 14 months). Of the two patients with rectal cancer, one achieved complete response, whereas the other showed no change. Both patients showed relief of symptoms, and no surgical intervention was required. Because HDR brachytherapy can be performed without radiation exposure other than to the patient, this procedure is useful to treat recurrent cancer, especially for elderly or frail patients. Superficially located or small tumors are the most likely candidates for this procedure. With more accurate selection of patients and prophylactic treatment, this procedure could be useful if no other treatment options remain.

    Scopus

    researchmap

  • 前立腺癌 査読

    能勢隆之, 井上武宏, 井上俊彦, 田中英一, 塩見浩也, 吉田謙, 中村仁信, 三木恒治, 小島康行, 野々村祝夫

    臨床放射線   41 ( 13 )   1643 - 1646   1996年

    　詳細を見る

    担当区分：筆頭著者  

    researchmap

  • 中咽頭癌 査読

    能勢隆之, 井上武宏, 井上俊彦, 田中英一, 手島昭樹, 塩見浩也, 吉田謙, 中村仁信, 服部賢二, 吉田淳一

    臨床放射線   41 ( 13 )   1617 - 1621   1996年

    　詳細を見る

    担当区分：筆頭著者  

    researchmap

  • 進行がんの治療 新しい治療 挑戦と限界 放射線 治療計画・適応症・効果判定 小線源照射

    井上俊彦, 能勢隆之, 小泉雅彦, 田中英一, 井上武宏, 村山重行, 手島昭樹

    綜合臨床   44 ( 8 )   1957 - 1961   1995年8月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(株)永井書店  

    J-GLOBAL

    researchmap

  • 3次元実体モデルを応用した小線源治療計画 査読

    小泉雅彦, 井上俊彦, 井上武宏, 山崎秀哉, 香川一史, 福島祥子, 松村聡子, 村山重行, 能勢隆之, 田中英一, 塩見宏也

    日本医学放射線学会雑誌   55 ( 8 )   603 - 605   1995年7月

    　詳細を見る

    掲載種別：研究論文（学術雑誌）  

    A 3D-simulation model made with a milling system was applied to HDR-brachytherapy. The 3D-simulation model is used to simulate the 3D-structure of the lesion and the surrounding organs before the actual catheterization for brachytherapy. The first case was recurrent prostatic cancer in a 61-year-old man. The other case was lymph node recurrence of a 71-year-old woman&#039;s upper gum cancer. In both cases, the 3D-simulation model was very useful to simulate the 3D-conformation, to plan the treatment process and to avoid the risk accompanying treatment.

    Scopus

    PubMed

    researchmap

  • 高線量率分割組織内照射を用いた中咽頭癌の放射線治療 査読

    能勢隆之, 井上俊彦, 井上武宏, 手島昭樹, 村山重行

    頭頚部腫瘍   21 ( 1 )   166 - 170   1995年3月

    　詳細を見る

    担当区分：筆頭著者   記述言語：日本語  

    DOI： 10.5981/jjhnc1974.21.166

    J-GLOBAL

    researchmap

  • Overall time in telecobalt therapy for T1 glottic carcinoma treated with 2 Gy per day 査読

    T. Inoue, T. Inoue, T. Teshima, S. Murayama, H. Yamazaki, T. Nose, E. Tanaka

    Strahlentherapie und Onkologie   171   475 - 477   1995年1月

    　詳細を見る

    Background/Aim: We already reported the tumor response during radiotherapy as a prognostic factor for T1 glottic carcinoma. In these reports, we did not evaluate the overall treatment time. There were many reports of correlation between local control and overall treatment time of radiation for head and neck cancer. Our aim was to evaluate the overall treatment time as a prognostic factor of the local control for T1 glottic carcinoma or not. Patients and Methods: From 1967 through 1985, 295 patients of T1 glottic carcinoma were treated with telecobalt therapy at the Department of Radiology, Osaka University Medical School. Of 295 patients, 219 patients treated with 2 Gy per day were evaluated. The median of total doses was 60 Gy (42 to 72 Gy). Overall treatment times of patients with tumor clearance at 40 Gy were significantly shorter than those with tumor persistence at 40 Gy. Results: According to the univariate analysis, there were no statistically significant factors for local control except tumor response during treatment. Of 124 patients treated with a total dose of 60 Gy and the overall treatment time of 40 to 46 days, local control rates of patients treated with the overall treatment time of 40 to 42 days and 43 to 46 days were 88% and 78%, respectively (p = 0.3072) For 91 patients with tumor clearance at 40 Gy, local control rates of patients treated with the overall treatment time of 40 to 42 days and 43 to 46 days were 96% and 82% respectively (p = 0.1645). Corresponding figures for 31 patients with tumor persistence at 40 Gy were 63% and 65% respectively (p = 0.4227) Conclusion: We compare the treatment results of patients treated with the same total dose and the same tumor response during radiotherapy. We concluded that the overall treatment time was not a prognostic factor for T1 glottic tumor treated with overall time of 40 to 46 days.

    Scopus

    PubMed

    researchmap

  • Radiotherapy for lung cancer: Comparison of results 628 patients treated with palliative and radical treatment 査読

    J. T. Tang, H. Yamazaki, T. Inoue, M. Koizumi, K. Kagawa, T. Nose, S. Murayama, M. Mori, E. Takeuchi, M. Ito, H. Ikeda, T. Inoue

    Cancer Journal   8   201 - 205   1995年1月

    　詳細を見る

    Background - The aim of this study was to investigate changes in survival rates and some prognostic factors for medically inoperable lung cancer treated by palliative and radical radiation therapy during the past three decades. Patients and Methods - We compared treatment results of 628 patients, divided into two groups according to treatment period (396 patients treated at Osaka University Hospital from 1967 to 1983 and 232 patients treated at National Toneyama Hospital from 1986 to 1991). All patients were affirmed medically inoperable. Advanced CT equipment and newly developed adjuvant chemotherapy were used at the National Toneyama Hospital. Moreover, the policy of radiotherapy had changed from palliative to radical treatment over this period. Results - There was no significant improvement in survival between the two groups. The 2- and 5-year survival rates were 10% and 4% for Osaka University Hospital and 12% and 1% for National Toneyama Hospital. In addition, we used Cox&#039;s multivariate analysis to examine factors which may influence survival. Although a high total dose and a small irradiation field were favorable prognostic factors, both factors were related to the clinical stage. Conclusion - No significant improvement was found to have been achieved for medically inoperable lung cancer by radiotherapy over the past three decades. The clinical stage (p &lt; 0.01) was almost the only important factor for long-term survival after radiotherapy.

    Scopus

    researchmap

  • Modified ovoid applicator for intracavitary radiation therapy with a Selectron-MDR or microSelectron-HDR 査読

    T. Teshima, T. Inoue, S. Ozeki, T. Inoue, M. Ohtani, T. Nose, H. Yamazaki, H. Ikeda, S. Murayama

    Radiation Medicine - Medical Imaging and Radiation Oncology   12   289 - 291   1994年12月

    　詳細を見る

    A modified ovoid applicator for intracavitary radiotherapy was developed for Japanese and other Asian women. It has more variations of smaller sized ovoids than the original rigid standard applicator of the Selectron-MDR and microSelectron-HDR. In addition, application of the ovoid pair and tandem flange is easy due to the flat surface of the inner aspect of the ovoid pairs, which prevents slippage of the ovoids and flange. The applicator is described together with source loading and dose distribution.

    Scopus

    PubMed

    researchmap

  • Modified Inoue applicator for endometrial brachytherapy 査読

    T. Teshima, T. Inoue, T. Inoue, M. Ohtani, H. Yamazaki, T. Nose, S. Ozeki, H. Ikeda, S. Murayama

    Radiation Medicine - Medical Imaging and Radiation Oncology   12   285 - 287   1994年12月

    　詳細を見る

    The Inoue applicator (3 channels) for endometrial cancer with a microSelectron-HDR was modified to enable both intrauterine and vaginal treatments to be done at the same time. The applicator is described together with a case report.

    Scopus

    PubMed

    researchmap

  • 1980年の放射線治療構造調査における病変部位別頻度の検討

    井上武宏, 井上俊彦, 手島昭樹, 山崎秀哉, 大谷雅俊, 能勢隆之, 大関修治, TONG K

    臨床放射線   39 ( 6 )   719 - 722   1994年6月

    　詳細を見る

    記述言語：日本語  

    J-GLOBAL

    researchmap

  • 1980年および1990年の放射線治療構造調査の比較検討

    井上武宏, 井上俊彦, 手島昭樹, 山崎秀哉, 唐けい天, 大谷雅俊, 能勢隆之, 大関修治

    臨床放射線   39 ( 3 )   379 - 382   1994年3月

    　詳細を見る

    記述言語：日本語  

    J-GLOBAL

    researchmap

  • Prognostic factors of radiation therapy for t3 and t4 laryngeal carcinoma 査読

    Takehiro Inoue, Toshihiko Inoue, Hideya Yamazaki, Jin Tiang Tang, Teruki Teshima, Masatoshi Ohtani, Takayuki Nose, Shuji Ozeki, Hiroshi Ikeda, Shigeyuki Murayama

    The Journal of JASTRO   6 ( 1 )   13 - 19   1994年1月

    　詳細を見る

    記述言語：英語   出版者・発行元：Japanese Society for Therapeutic Radiology and Oncology  

    Local control rates for T3 and T4 laryngeal carcinoma treated with radiation alone have been reported as 42 to 63% and 18 to 56%, respectively. We investigated the factors which affect survival and local control rates for T3 and T4 laryngeal carcinoma. From 1967 through 1985, 43 advanced laryngeal carcinoma (T3: 14, T4: 29) cases were treated with radical radiotherapy and 35 (T3: 14, T4: 21) with preoperative radiotherapy at the Department of Radiology, Osaka University Hospital. The 5-year cause-specific survival rates for T3 and T4 cases treated with radical radiotherapy were 48% and 52%, and for those treated with preoperative radiation 71% and 43%, respectively. No statistically significant differences were found between cause-specific survival rates for cases treated with radical radiotherapy and preoperative groups. The 5- and 10-year cause-specific survival rates for NO cases treated with radical radiation were 67% and 67% and those for N+ cases 42% and 25%, respectively. Cause-specific survival rates for NO cases were significantly higher than for N+ cases (p&lt;0.05). The 5-year local control rates for T3 and T4 cases treated with radical radiation were 48% and 24%, respectively. Ultimate local control rates for tumors with invasion of the base of the tongue (13%) were significantly lower than that for those with invasion of other sites (67%) (p=0.034). Nodal metastasis proved to be an important prognostic factor for T3-4 laryngeal carcinoma treated with radical radiation, and base of the tongue invasion for T4 supraglottic carcinoma. © 1994, Japanese Society for Therapeutic Radiology and Oncology. All rights reserved.

    DOI： 10.11182/jastro1989.6.13

    Scopus

    researchmap

  • 特集 癌治療における放射線科領域最近の進歩 192Ir小線源治療

    井上俊彦, 井上武宏, 山崎秀哉, 大関修治, 手島昭樹, 大谷雅俊, 能勢隆之, TANG J T

    癌と化学療法   20 ( 14 )   2120 - 2125   1993年11月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(株)癌と化学療法社  

    J-GLOBAL

    researchmap

▼全件表示

書籍等出版物

  • 頭頸部の診断と治療 update

    能勢隆之, 編)黒崎喜久, 山下孝（ 担当： 分担執筆 範囲: 小線源治療の変遷）

    金原出版  2008年10月 

    　詳細を見る

MISC

  • 小線源治療の現在地 当院におけるAPBIの手技

    吉田 謙, 吉田 岑雄, 山崎 秀哉, 古妻 理之, 増田 慎三, 徳田 由紀子, 栗山 啓子, 能勢 隆之

    日本放射線腫瘍学会誌   20 ( 2 )   80 - 80   2008年6月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本放射線腫瘍学会  

    researchmap

  • 乳房温存術後の高線量率組織内照射単独療法

    吉田 謙, 能勢 隆之, 山崎 秀哉, 吉田 岑雄, 樽井 利明, 三上 麻里, 武中 正, 大住 隆, 徳田 由紀子, 栗山 啓子, 竹田 雅司, 増田 慎三

    日本放射線腫瘍学会誌   19 ( 3 )   232 - 232   2007年9月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本放射線腫瘍学会  

    researchmap

  • 前立腺癌高線量率組織内照射における治療期間中のアプリケータ偏位について

    三上 麻里, 吉田 謙, 山崎 秀哉, 吉田 岑雄, 能勢 隆之, 塩見 浩也, 樽井 利明, 武中 正, 上垣 忠明, 大住 隆, 栗山 啓子, 岡 聖次

    日本放射線腫瘍学会誌   19 ( 3 )   225 - 225   2007年9月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本放射線腫瘍学会  

    researchmap

  • ガラス線量計Dose Aceを用いた組織内照射における線量実測-骨盤部1,004点の実測-

    能勢隆之, 小泉雅彦, 吉田謙, 佐々木潤一, 西山謹司, 小塚拓洋, 五味光太郎, 小口正彦, 高橋豊, 山下孝

    日本放射線腫よう学会誌   17 ( Supplement 1 )   2005年

    　詳細を見る

  • 中咽頭癌に対する高線量率組織内照射

    能勢 隆之, 小泉 雅彦, 西山 謹司

    頭頚部腫瘍   30 ( 2 )   170 - 170   2004年5月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本頭頸部癌学会  

    CiNii Books

    CiNii Research

    researchmap

  • 温存乳房内再発からみた乳房温存療法の検討 大阪府立成人病センターでの長期追跡結果を中心に

    稲治 英生, 柳沢 哲, 菰池 佳史, 元村 和由, 小山 博記, 小泉 雅彦, 能勢 隆之, 西山 謹司

    癌治療と宿主   16 ( 2 )   169 - 169   2004年4月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(株)メディカルレビュー社  

    researchmap

  • 下咽頭癌に対する3D boost併用放射線治療の初期経験

    西山謹司, 小泉雅彦, 能勢隆之

    日本医学放射線学会雑誌   64 ( 3 )   2004年

    　詳細を見る

  • 子宮癌に対する高線量率組織内照射治療の検討

    古元淑子, 天満久美子, 太田行信, 山本敏也, 森重健一郎, 上浦祥司, 佐治文隆, 小泉雅彦, 能勢隆之

    日本癌治療学会誌   38 ( 2 )   2003年

    　詳細を見る

  • 組織内照射を用いた乳房温存療法

    菰池 佳史, 能勢 隆之, 元村 和由, 稲治 英生, 小泉 雅彦, 西山 謹司, 小山 博記

    日本癌治療学会誌   37 ( 2 )   195 - 195   2002年9月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本癌治療学会  

    J-GLOBAL

    researchmap

  • N2梨状陥凹癌に対する治療戦略 放射線治療の立場から

    西山 謹司, 小泉 雅彦, 能勢 隆之, 上村 裕和, 藤井 隆, 吉野 邦俊

    頭頸部腫瘍   28 ( 2 )   352 - 352   2002年5月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本頭頸部癌学会  

    researchmap

  • EBMとPCSからみた臓器別放射線治療法?前立腺癌?

    中村和正, 手島昭樹, 高橋豊, 今井敦, 小泉雅彦, 能勢隆之, 三橋紀夫, 井上俊彦, 日本PCS前立腺癌小線源部会

    日放腫会誌   14 ( 2 )   79 - 85   2002年

    　詳細を見る

  • Lumpectomy+組織内照射単独による乳房温存療法

    能勢隆之, 小泉雅彦, 西山謹司, 吉田謙

    日本医学放射線学会雑誌   62 ( 3 )   2002年

    　詳細を見る

  • CTV-based Dose Prescriptionにおける金属マーカーの有効性

    吉田謙, 能勢隆之, 小泉雅彦, 吉田みね雄, 西山謹司, 御供政紀

    日本医学放射線学会雑誌   62 ( 3 )   2002年

    　詳細を見る

  • リンパ節転移陽性乳癌に対する乳房温存手術後の補助療法 放射線療法と化学療法のsequenceに関する検討

    稲治 英生, 菰池 桂史, 元村 和由, 小山 博記, 小泉 雅彦, 能勢 隆之, 西村 謹司

    癌治療と宿主   13 ( 4 )   372 - 372   2001年10月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(株)メディカルレビュー社  

    researchmap

  • 下咽頭癌の機能温存療法の現状と将来(放射線科の立場から)

    西山 謹司, 小泉 雅彦, 能勢 隆之, 藤井 隆, 吉野 邦俊

    頭頚部腫瘍   27 ( 2 )   307 - 307   2001年5月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本頭頸部癌学会  

    CiNii Books

    CiNii Research

    researchmap

  • 肺癌原体照射の初期経験

    西山謹司, 小泉雅彦, 能勢隆之

    日本放射線腫よう学会誌   13 ( Supplement 1 )   2001年

    　詳細を見る

  • 中咽頭癌に対する高線量率組織内照射

    能勢隆之, 小泉雅彦, 西山謹司, 吉田謙, 井上俊彦

    日本放射線腫よう学会誌   13 ( Supplement 1 )   2001年

    　詳細を見る

  • 三次元原体照射のリーフマージンの検討

    小泉雅彦, 能勢隆之, 西山謹司

    日本医学放射線学会雑誌   61 ( 8 )   2001年

    　詳細を見る

  • 【乳癌診療の最前線】乳房温存療法をめぐる諸問題 その他の問題 乳房内再発 とくに炎症性乳癌型再発についての考察

    稲治 英生, 菰池 佳史, 元村 和由, 小山 博記, 能勢 隆之, 小泉 雅彦, 春日井 努

    癌の臨床   46 ( 5 )   677 - 682   2000年5月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(株)篠原出版新社  

    researchmap

  • Micro-Multi-Leaf (m3 ^<TM>) を用いた頭頸部癌の定位放射線治療

    西山 謹司, 小泉 雅彦, 能勢 隆之, 吉野 邦俊

    頭頚部腫瘍   26 ( 1 )   127 - 132   2000年3月

    　詳細を見る

  • 定位照射の線量分布 マイクロ・マルチ・リーフm3とコーンの比較

    小泉雅彦, 能勢隆之, 西山謹司

    日本医学放射線学会雑誌   60 ( 8 )   2000年

    　詳細を見る

  • 声門上部癌の治療成績

    小泉雅彦, 能勢隆之, 西山謹司, 真崎規江

    日本医学放射線学会雑誌   60 ( 4 )   2000年

    　詳細を見る

  • Micro-Multi-Leafを用いた神経こう芽腫の定位照射

    西山謹司, 小泉雅彦, 能勢隆之

    日本医学放射線学会雑誌   60 ( 2 )   2000年

    　詳細を見る

  • 下腿脂肪肉腫の術前定位放射線治療の1例

    小泉雅彦, 能勢隆之, 西山謹司

    日本医学放射線学会雑誌   60 ( 13 )   2000年

    　詳細を見る

  • パリ法による組織内照射 新旧2法の比較

    能勢隆之, 西山謹司, 小泉雅彦

    日本医学放射線学会雑誌   60 ( 2 )   2000年

    　詳細を見る

  • 前立腺癌に対する高線量率組織内照射

    吉田 謙, 能勢 隆之, 井上 俊彦, 井上 武宏, 山崎 秀哉, 田中 英一, 塩見 浩也, 今井 敦

    日本癌治療学会誌   33 ( 3 )   188 - 188   1998年8月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本癌治療学会  

    researchmap

  • 画像医学の進歩と放射線治療医の対応 医用画像の治療計画への応用-密封小線源治療について

    能勢隆之, 井上俊彦, 井上武宏, 村山重行, 小泉雅彦, 香川一史, 井上均

    日本放射線腫よう学会誌   6 ( Suppl 2 )   1994年

    　詳細を見る

  • ラジオアイソトープの治療への応用 V.新しい小線源治療-192Ir高線量率照射-

    井上 俊彦, 井上 武宏, 能勢 隆之

    RADIOISOTOPES   43 ( 12 )   798 - 808   1994年

    　詳細を見る

  • RADIATION-THERAPY FOR NASOPHARYNGEAL CARCINOMA - RETROSPECTIVE REVIEW OF 105 PATIENTS BASED ON A SURVEY OF KANSAI CANCER THERAPIST GROUP

    M CHATANI, T TESHIMA, T INOUE, AZUMA, I, H YOSHIMURA, T OSHITANI, M HASHIBA, K NISHIYAMA, K TSUTSUI, T FUJIMURA, Y ARAKI, Y HISHIKAWA, S ARITA, C YAMADA, K KONDO, M KAGEMOTO, M TANAKA, Y IMAJO

    CANCER   57 ( 12 )   2267 - 2271   1986年6月

    　詳細を見る

    記述言語：英語   出版者・発行元：WILEY-LISS  

    DOI： 10.1002/1097-0142(19860615)57:12<2267::AID-CNCR2820571205>3.0.CO;2-C

    Web of Science

    researchmap

▼全件表示